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1. Introduction 
Colchicine has been shown rapidly to block the 
secretion of serum proteins, including VLDL [l-4] 
and albumin [4]. The VLDL accumulates in Golgi- 
derived secretory vesicles [ I] , possibly from interference 
with the microtubular system [2 3 and causes fatty liver 
[l-4] . Since cholesterol is an important component of 
lipoproteins, the inhibition of VLDL release provides 
an interesting model for studying the role of hepatic 
cholesterol synthesis in serum lipoprotein formation. 
Other drugs which lower serum VLDL levels and 
induce fatty liver differ from each other in their 
effects on cholesterogenesis. Thus, carbon tetrachloride 
inhibits [S] , but erotic acid stimulates cholesterol 
synthesis [6]. Accordingly, since the effect of col- 
chicine was unpredictable, we established experimental 
conditions to test the opposite hypotheses that the 
drug has a stimulatory or inhibitory effect on the 
sterol’s production and on HMG CoA reductase 
(mevalonate: NADP oxidoreductase (acylating CoA) 
EC 1 .l .1.34), the rate-controlling enzyme for choles- 
terol synthesis. 
2. Materials and methods 
2.1. Treatment schedules (fig. I) 
Male or female Holtzman rats weighing between 
180 and 250 g and housed one to a cage were fed 
according to our previously described controlled 
lighting and feeding schedule [7]. Lights were 
automatically turned off at 9:00 a.m. and on at 9:00 
p.m. daily and food was placed in cages at 9:00 a.m. 
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and removed at 5:00 p.m. Since rats are nocturnal 
feeders, reversal of the lighting provides optimal 
conditions for adapting the feeding pattern to daylight 
hours. The rats were cyclically fed according to this 
8 h feeding-l 6 h fasting schedule for at least one 
week, but food was withheld on the day of sacrifice. 
In one set of experiments, cholesterol synthesis was 
determined in rats fed a previously described diet, 
containing 0% fat, 20% protein, and 75% dextrose, 
that was shown to induce low levels of HMG CoA 
reductase activity [7]. Groups of rats were injected 
with three separate doses of either 0.1 mg 
(Experiment IA) or 0.125 mg (Experiment 1B) 
of colchicine i.p. and subsequently injected with 
10 mCi of 3Hz0 i.p. 90 min prior to sacrifice. The 
amount of tritium incorporated into digitonin- 
precipitated sterol recovered from livers under these 
conditions is considered a valid measurement of 
in vivo hepatic cholesterol synthesis [8,9]. 
In a second series of experiments (IIA,B,C), rats 
were cyclically fed a diet containing 20% corn oil, 
2% cholestyramine, 20% protein, 3 1% dextrose, and 
22% cellulose [7]. This diet was previously shown 
to induce a high level of HMG CoA reductase activity 
[7]. In order to determine the effect of colchicine on 
this induction and on the synthesis of cholesterol, a 
single dose of 0.2 mg colchicine was injected at 
midnight and rats were then sacrificed at 8:00 a.m. or 
9:30 a.m. (fig.1). When cholesterol synthesis was 
determined, rats were injected with 10 mCi of 
3Hz0 i.p. 90 min prior to sacrifice. Rats used as 
controls in all studies were injected with volumes of 
isotonic saline equivalent to the volumes of colchicine 
solution. 
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Fig.1. Treatment schedule of rats in various experiments. Female Holtzman rats fed the 0% fat diet were used in Exp. IA and IB 
and male Holtzman rats were used in Exp. IIA, IIB and IIC. Lighting and prior feeding-fasting schedules are indicated in the lower 
part of the chart. Colchicine (C) was prepared as a 0.5% solution in isotonic saline and injected i.p. at the indicated dosages and 
times. 10 mCi 3H,0 were injected i.p. 90 min prior to sacrifice in the indicated experiments. 
2.2. Lipid assay methods 
In the earlier experiments (IA and IB) non-saponifi- 
able lipids were extracted by heating the liver in alco- 
holic KOH, extracting three times with chloroform, 
evaporating the solvent, suspending the lipid residue 
in water, and re-extracting with petroleum ether [lo] . 
In the later experiments, lipids were separated from 
1 g aliquots of liver by the method of Folch et al. [ 111. 
Complete removal of 3Hz0 from the chloroform- 
methanol extracts was insured by repeated washing 
of the ‘Folch lower phase’ with 1: 1 mixtures of 
CH30H:0.76% KC1 solution. Measured aliquots were 
taken for triglyceride [12] and cholesterol determina- 
tions. The latter were dried under nitrogen and the 
residues saponified in alcoholic KOH. The non- 
saponifiable lipid was extracted with petroleum ether. 
Digitonides were prepared from the petroleum ether 
extracts by the method of Sperry and Webb [13]. 
The precipitated digitonide was washed and resus- 
pended in glacial acetic acid [13] . For radioactivity 
.determination, 1 cc. samples were dissolved in 10 cc. 
Tulene PPO. In some studies, samples in glacial acetic 
acid were taken for cholesterol determination by the 
method of Zak [14]. 
HMG CoA reductase activity was determined by a 
modification [7] of our previously described method 
[ 151. The specific activity of the [‘“Cl HMG CoA 
substrate was 3.7 X lo6 dpm/pmole. 
3. Results and discussion 
Nine hours after a single i.p. injection of 0.2 mg 
colchicine into rats fed the hypercholesterogenic diet 
(Exp. HA), the hepatic triglyceride level had increased 
more than 2.5fold (table 1). However, the level of 
hepatic cholesterol had not changed. In this same 
experiment cholesterol synthesis, measured by incor- 
poration of 3Hz0 into digitonin precipitated sterol, 
was 57% lower than in controls (table 2). The level 
of HMG CoA reductase activity was decreased by 75% 
and 68% respectively in rats injected with colchicine 
9.5 and 8 h prior to sacrifice. Rats fed the fat-free diet 
and injected with three doses of colchicine totalling 
3.75 mg/lOO g body weight and sacrificed after 5 h 
(Exp. IA) and those injected with doses of colchicine 
totalling 3.0 mg and sacrificed after 6.5 h (Exp. IB) 
respectively showed 97% and 95% reduction in 
cholesterogenesis (table 2). 
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Table 1 
Hepatic triglyceride and cholesterol in rats fed 2% 
cholestyramine and 20% corn oil diet 
(Experiment HA) and injected with 0.2 mg of colchicine 
or saline i.p. and sacrificed after 8 h. 
Colchicine (5) Saline (5) Significance 
Cholesterol 
mg/g liver 2.3 f 0.4a 2.1 ,f 0.1 N.S. 
Triglyceride 
mg/g liver 11.1 f 1.6 4.5 f 1.4 P< 0.001 
The number of rats in each group is indicated in parentheses. 
a Standard deviation. 
In this study the inhibition of cholesterol synthesis 
by colchicine was demonstrated under two entirely 
different kinds of experimental conditions. In the 
earlier experiments, rats fed a fat-free diet were 
injected with repeated small doses of colchicine. The 
drug reduced the already low fasting level of cholestero- 
genesis to a striking degree. Since it was not possible 
accurately to measure changes in the low level of HMG 
CoA reductase activity under these conditions, we then 
studied the inhibitory effect in rats fed a high fat diet 
containing cholestyramine. Here, too, the level of 
cholesterogenesis was significantly reduced - this time 
after a single dose of 0.2 mg colchicine/lOO g body 
weight. The almost proportionate reduction of HMG 
CoA reductase activity in rats fed this hypercholestero- 
genie diet suggests that the colchicine effect is at the 
level of the rate controlling enzyme. 
All experiments were purposely carried out late in 
the fasting period in order to avoid any effect that 
colchicine might have on feeding behavior. This is 
important since the feeding pattern affects the diurnal 
rhythm of cholesterogenesis and HMG CoA reductase 
activity [I 6,171. We have shown that HMG CoA 
reductase activity doubles between midnight and 8 
a.m. in rats fed the diet containing 20% corn oil and 
2% cholestyramine [7]. Colchicine injection effectively 
blocked this induction since experimental rats showed 
less than 50% of the level of HMG CoA reductase 
activity and cholesterogenesis noted in control rats. 
Previously we speculated that the induction of HMG 
CoA reductase activity during this fasting period 
reflected an adaptive increase in bile acid synthesis 
for the subsequent high fat meal [7]. However, since 
colchicine injection caused a 250% increase in the 
level of hepatic triglyceride, a block in excretion of 
nascent VLDL might have caused the accumulation 
of a small, but critically located, pool of cholesterol 
that prevented the induction of HMG CoA reductase 
activity [ 181. Accordingly, we suggest hat the 
enzyme increase induced by dietary lipid reflects a 
need for newly synthesized cholesterol for VLDL 
production. The hypothesis is consistent with the 
observations that VLDL is the primary lipoprotein 
secreted by the liver and that it is much more rapidly 
Table 2 
Tritium incorporation into digitonin-precipitated sterol of liver and hepatic microsomal HMG CoA reductase activity in control 
and experimental animals on the different treatment schedules hown in fig.1. 
Digitonin-pptd. sterol 
dpm/g liver 
Exp. Colchicine Saline 
HMG CoA reductase activity 
(pmole mevalonate/mg microsomal protein/h) 
Colchicine Saline Significance 
IIC - _ 10.7 * 2.1 (5) 33.6 ? 8.7 (5) P < 0.001 
IIB 
IIA 
IB 
- _ 9.7 * 3.2 (5) 38.6 f 4.9 (5) P < 0.001 
10 356 + 2363 (6) 24 130 * 6716 (6) - - P< 0.01 
98 + 41 (3) I647 + 467 (3) _ - P < 0.02 
IA 
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metabolized than the other smaller serum lipoproteins 
[19] . It is also unlikely that the reduction of choles- 
terol synthesis by colchicine reflects a decrease in 
excretion of biliary sterols. This is suggested since col- 
chicine does not affect biliary cholesterol and bile 
flow [3]. Since bile acid excretion is the major 
determinant of bile flow [20], it is therefore unlikely 
that bile acid excretion is affected by colchicine. 
Colchicine was selected for this study because it is 
rather specific in the way in which it blocks the 
release of serum proteins. In contrast to ethionine 
[21], and carbon tetrachloride [22] which also 
decrease the level of circulating VLDL, it does not 
interfere with protein synthesis at the levels used in 
this experiment [3]. In addition it does not block the 
early steps in the secretory process nor, as in the case 
of erotic acid [2], does it alter the size of the intra- 
hepatic nucleotide pool [4]. However, the drug does 
affect nucleoside transport [23]. Therefore, in order 
to further validate the use of colchicine as a tool for 
studying the integration of cholesterol and serum 
lipoprotein synthesis, its effect on cholesterol synthe- 
sis should be compared with that of lumicoichicine, a 
structural analog [24]. This comparison might be 
valuable since lumicolchicine has only a minimal effect 
on secretory protein release [4] but it does show 
some of the other effects of colchicine including the 
decrease in nucleoside transport [25] . 
Acknowledgement 
This work was supported by NIH grant CA-1 5664. 
References 
[II 
121 
131 
141 
151 
161 
171 
181 
PI 
1101 
I111 
IL21 
1131 
1141 
1151 
1161 
1171 
1181 
I191 
I201 
1211 
1221 
1231 
1241 
I251 
Stein, 0. and Stein, Y. (1973) Biochim. Biophys. Acta 
306,142-147. 
LeMarchand, Y., Singh, A., Assimacopoulos-Jeannet, F., 
Orci, L., Rouiller, C. and Jeanrenaud, B. (1973) J. Biol. 
Chem. 248,6862-6870. 
Stein, O., Sanger, L. and Stem, Y. (1974) J. Cell. Biol. 
62,90-103. 
Redman, C. M., Banerjee, D., Howell, K. and Palade, G. E. 
(1975) J. Cell. Biol. 66, 42-59. 
Cans, J. H. (1973) Biochim. Biophys. Acta 326,116-126. 
Windmueller, H. G. and Spaeth, A. E. (1966) J. Biol. 
Chem. 241,2891-2899. 
Goldfarb, S. and Pitot, H. C. (1972) J. Lipid Res. 13, 
797-801. 
Brunengraber, H., Sabine, J. R., Boutry, M. and 
Lowenstein, J. M. (1972) Arch. Biochem. Biophys. 150, 
392-396. 
Brunengraber, H., Boutry, M. and Lowenstein, J. M. 
(1973) J. Biol. Chem. 248,2656-2669. 
Entenman, C. (1957) in: Methods in Enzymol., Vol. III, 
313. 
Folch, J., Lees, M. and Sloane-Stanley, G. H. (1957) 
J. Bioi. Chem. 226,497-509. 
Van Handel, E. and Zilversmit, D. B. (1957) J. Lab. Clin. 
Med. 50,152-157. 
Sperry, W. M. and Webb, M. (1950) J. Biol. Chem. 187, 
97-106. 
Zak, B. (1965) Stand. Methods of Clinical Chem. 5, 
79-89. 
Goldfarb, S. and Pitot, H. C. (1971) J. Lipid Res. 12, 
512-515. 
Kandutsch, A. A. and Saucier, S. E. (1969) 3. Biol. Chem. 
244,2299-2305. 
Hamprecht, B., Nussler, C. and Lynen, F. (1969) FEBS 
Lett. 4,117-121. 
Erickson, S. K., Davison, A. M. and Gould, R. G. (1975) 
Biochim. Biophys. Acta 409,59-67. 
Levy, R. I., Bilheimer, D. W. and Eisenberg, S. (1971) 
Biochem. Sot. Symp. 33, 3-17. 
Sperber, I. (1959) Pharmacol. Rev. 11, 109-134. 
Farber, E. (1967) Advances Lipid Res. 5,119-183. 
Lombardi, B. and Ugazio, G. (1965) J. Lipid Res. 6, 
498-505. 
Windmueller, H. G. (1965) 3. Nutr. 85,221-229. 
Mizel, S. B. and Wilson, L. (1972) Biochemistry 11, 
2513-2518. 
Wilson, L. (1974) Adv. Cell. Mol. Biology 3,21-72. 
349 
